Physician profile
Calee Stephens Britt
NPI 1295123792
$3,257.71
in general payments reported to CMS, 2019-2025
20 companies · $508 in 2025
The $508 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $556 · 2022: $296 · 2023: $924 · 2024: $973 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,405.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,928.07 | 2021-2025 | |
| Novo Nordisk INC | $358.07 | 2021-2023 | Ozempic, Rybelsus |
| Allergan, INC. | $225.60 | 2022 | |
| Inspire Medical Systems, INC. | $111.65 | 2024 | Inspire |
| Lilly USA, LLC | $98.32 | 2021-2024 | Trulicity, Mounjaro, Zepbound |
| Amgen INC. | $97.11 | 2021-2024 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $76.22 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $71.88 | 2023-2024 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $44.60 | 2021 | |
| Pfizer INC. | $43.23 | 2023-2024 | |
| Astellas Pharma US INC | $40.90 | 2023 | Veozah |
| Merck Sharp & Dohme LLC | $24.24 | 2023 | Steglatro, Janumet, Belsomra |
| Glaxosmithkline, LLC. | $23.79 | 2021 | |
| Supernus Pharmaceuticals, INC. | $22.85 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.88 | 2023 | Xifaxan |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Linus Health, INC. | $15.80 | 2023 | |
| Galderma Laboratories, L.P. | $14.53 | 2022 | |
| Azurity Pharmaceuticals, INC. | $14.39 | 2023 | Adthyza |
| Lundbeck LLC | $14.32 | 2023 | Rexulti |
| Acella Pharmaceuticals, LLC | $14.26 | 2025 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Calee Britt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.